Update on the reimbursement process in France
The next steps will be the final approval by the French Health Ministry and a price decision by the Economic Committee for Health Product (CEPS).
The Transparency Committee decided to propose for reimbursement for Glucomed with one condition: A clinical study demonstrating the capacity of Glucomed to reduce the consumption of NSAIDs among osteoarthritis patients treated with Glucomed must be performed within 2 years. The reimbursement status will be reevaluated when the study is performed.
Navamedic and its French partner are preparing for the requested clinical study. A first step will be to evaluate the costs and how to perform the clinical study. More information will be given in the Q2-presentation August 19th.
For further information, please contact:
Bernt-Olav Røttingsnes, CFO Navamedic ASA
E-mail: bor [at] navamedic [dot] com
Office: +47 67 11 25 44
Mobile: +47 91 34 70 21